Cargando…

Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia

Detalles Bibliográficos
Autores principales:	Kurtin, Sandra E., Matta, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093431/ https://www.ncbi.nlm.nih.gov/pubmed/25032006

Ejemplares similares

Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
por: Chen, Yaoyu, et al.
Publicado: (2014)

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
por: Akard, Luke, et al.
Publicado: (2015)

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses
por: Wetzler, M, et al.
Publicado: (2015)

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
por: Nemunaitis, John, et al.
Publicado: (2012)

Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines
por: Kulkarni, Hemant, et al.
Publicado: (2012)

A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected
por: Winer, Eric S., et al.
Publicado: (2018)

Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B-cell lymphoma cells
por: ZHANG, LINA, et al.
Publicado: (2016)

Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

The choice of first-line Chronic Myelogenous Leukemia treatment
por: Fava, Carmen, et al.
Publicado: (2015)

Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-Induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice
por: Chen, Yaoyu, et al.
Publicado: (2009)

Biomarkers for determining the prognosis in chronic myelogenous leukemia
por: Sweet, Kendra, et al.
Publicado: (2013)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
por: Janani, Gopalarethinam, et al.
Publicado: (2023)

Optimizing Treatment of Chronic Lymphocytic Leukemia
por: Kurtin, Sandra E.
Publicado: (2021)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
por: Ross, Theodora S, et al.
Publicado: (2014)

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors
por: Nijenhuis, Cynthia M., et al.
Publicado: (2016)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma
por: Li, Ling, et al.
Publicado: (2021)

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
por: Flis, Sylwia, et al.
Publicado: (2019)

Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach
por: Keramatinia, Aliasghar, et al.
Publicado: (2017)

Role of Lysophospholipid Metabolism in Chronic Myelogenous Leukemia Stem Cells
por: Naka, Kazuhito
Publicado: (2021)

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
por: Long, Bing, et al.
Publicado: (2011)

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014)

Risk Assessment and Risk-Adapted Treatment Selection: A Case-Based Approach for Chronic Lymphocytic Leukemia
por: Kurtin, Sandra, et al.
Publicado: (2017)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia
por: Chakraborty, Sandip N., et al.
Publicado: (2016)

Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells
por: Matsushita, Maiko
Publicado: (2021)

Chronic myelogenous leukemia in a child following treatment for bilateral retinoblastoma
por: Al-Mahrouqi, Haitham Hilal, et al.
Publicado: (2021)

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
por: Ono, Takaaki
Publicado: (2021)

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole, Josephine, et al.
Publicado: (2016)

Primary hyperparathyroidism in a case of chronic myelogenous leukemia
por: Valizadeh, Nasim, et al.
Publicado: (2013)

Unusual T-Lymphoblastic Blast Phase of Chronic Myelogenous Leukemia
por: Xu, Jie, et al.
Publicado: (2014)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p4bdj0qtf5tueq66om6djv9jcl